Outcomes and survival trends following pelvic exenteration for locally advanced and recurrent rectal cancer: a 20-Year analysis from a tertiary cancer center in India

印度一家三级癌症中心对局部晚期和复发性直肠癌患者行盆腔脏器切除术后的预后和生存趋势进行了20年分析

阅读:1

Abstract

BACKGROUND: Pelvic exenteration (PE) offers a potential cure for selected patients with Locally Advanced Rectal Cancer (LARC) or Locally Recurrent Rectal Cancer (LRRC) invading adjacent pelvic organs. Despite advances in surgical technique and perioperative care, PE remains associated with significant morbidity. This study evaluates long-term oncologic outcomes of PE over 20 years at a high-volume tertiary cancer center in India. METHODS: We retrospectively analysed 97 patients who underwent PE between January 2000 and December 2020. Patients included those with LARC or LRRC, where R0 resection was deemed feasible. Surgical procedures were classified as total pelvic exenteration (TPE) or modified pelvic exenteration (MPE). Data on demographics, operative parameters, pathological features, recurrence pattern and survival were analysed. RESULTS: Among the 97 patients (median age 59; 80.4% male), 67% had LARC and 33% LRRC. R0 resection was achieved in 71.1%. TPE was more common in LRRC, while MPE predominated in LARC (p = 0.014). Common complications included pelvic collection (25.8%) and wound infection (15.5%). The 5-year OS was higher in R0 resection patients (51.9% vs. 12.9%; p = 0.013) and those with LARC vs. LRRC (57.0% vs. 10.6%; p = 0.032). LRRC had higher recurrences post R0 resection. In the multivariate analysis, the only independent predictors of OS were the initial presentation of the disease and R0 resection. CONCLUSION: PE remains a curative strategy for LARC and LRRC following an R0 resection. LRRC is associated with higher recurrence and poorer survival. Optimal outcomes require multidisciplinary evaluation, margin-negative resection, and tailored surgical approaches. This study provides data from a low- and middle-income country setting, where such literature remains limited.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。